Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Harris VK, et al. J Neurol Sci. 2012 Feb 15;313(1-2):167-77. doi: 10.1016/j.jns.2011.08.036. Epub 2011 Oct 1. J Neurol Sci. 2012. PMID: 21962795
Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.
Harris VK, Sadiq SA. Harris VK, et al. Mol Diagn Ther. 2009;13(4):225-44. doi: 10.1007/BF03256329. Mol Diagn Ther. 2009. PMID: 19712003 Review.
Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis.
Harris VK, Diamanduros A, Good P, Zakin E, Chalivendra V, Sadiq SA. Harris VK, et al. Neurobiol Dis. 2010 Oct;40(1):331-9. doi: 10.1016/j.nbd.2010.06.007. Epub 2010 Jun 19. Neurobiol Dis. 2010. PMID: 20600910
Mesenchymal stem cells enhance the engraftment and myelinating ability of allogeneic oligodendrocyte progenitors in dysmyelinated mice.
Cristofanilli M, Harris VK, Zigelbaum A, Goossens AM, Lu A, Rosenthal H, Sadiq SA. Cristofanilli M, et al. Among authors: harris vk. Stem Cells Dev. 2011 Dec;20(12):2065-76. doi: 10.1089/scd.2010.0547. Epub 2011 Mar 12. Stem Cells Dev. 2011. PMID: 21299379
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
Harris VK, Faroqui R, Vyshkina T, Sadiq SA. Harris VK, et al. Stem Cells Transl Med. 2012 Jul;1(7):536-47. doi: 10.5966/sctm.2012-0015. Epub 2012 Jun 28. Stem Cells Transl Med. 2012. PMID: 23197858 Free PMC article. Clinical Trial.
Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis.
Harris VK, Donelan N, Yan QJ, Clark K, Touray A, Rammal M, Sadiq SA. Harris VK, et al. Mult Scler. 2013 Oct;19(11):1462-72. doi: 10.1177/1352458513477923. Epub 2013 Feb 25. Mult Scler. 2013. PMID: 23439582
Biomarkers of therapeutic response in multiple sclerosis: current status.
Harris VK, Sadiq SA. Harris VK, et al. Mol Diagn Ther. 2014 Dec;18(6):605-17. doi: 10.1007/s40291-014-0117-0. Mol Diagn Ther. 2014. PMID: 25164543 Free PMC article. Review.
Stem cell therapy in multiple sclerosis: a future perspective.
Harris VK, Sadiq SA. Harris VK, et al. Neurodegener Dis Manag. 2015;5(3):167-70. doi: 10.2217/nmt.15.6. Neurodegener Dis Manag. 2015. PMID: 26107312 Free article. No abstract available.
Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK, Vyshkina T, Sadiq SA. Harris VK, et al. Cytotherapy. 2016 Dec;18(12):1476-1482. doi: 10.1016/j.jcyt.2016.08.007. Epub 2016 Oct 7. Cytotherapy. 2016. PMID: 27727015
Fetuin-A deficiency protects mice from Experimental Autoimmune Encephalomyelitis (EAE) and correlates with altered innate immune response.
Harris VK, Bell L, Langan RA, Tuddenham J, Landy M, Sadiq SA. Harris VK, et al. PLoS One. 2017 Apr 7;12(4):e0175575. doi: 10.1371/journal.pone.0175575. eCollection 2017. PLoS One. 2017. PMID: 28388685 Free PMC article.
27 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page